Medindia

X

Rudd Report Updates AMDL's Achievements; Predicts Significantly Improved Future Operating Results

Wednesday, September 5, 2007 General News J E 4
Advertisement
TUSTIN, Calif., Sept. 4 AMDL, Inc. (Amex: ADL),headquartered in Tustin, California, with operations in Shenzhen, Jiangxi andJilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc., isan international biopharma company. AMDL together with Jade, engages in thedevelopment, manufacture and marketing of proprietary pharmaceutical anddiagnostic products. Set forth in this news release are highlights of therecent Rudd Report including AMDL's achievements as cited by Mr. Rudd. Mr.Rudd, a nationally syndicated columnist, is CEO of Savannah CapitalManagement, a money management firm.

About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com.

About Jade: Jade has access to the fastest growing pharmaceutical andconsumer market in the world: China. AMDL, through its subsidiaries, Jadecurrently manufactures large volume injection fluids, tablets and otherrelated products, holding licenses for 133 products. It also manufactures 107generic, over the counter and supplemental pharmaceutical products undercertified Chinese Good Manufacturing Practice (CGMP) standards.

About The Rudd Report Disclaimer: This disclaimer is an integral part ofour service. Please read it before investing in any security on which wereport. Opinions are solely those of the staff of The Rudd Report and aresubject to change without notice. Our reports are for information only and wedo not offer securities or solicit the offer of securities of any company.Our reports are to inform the public and not to promote any company or itssecurities. We do not inform any company in advance of the nature orconclusions of our reports nor can a company change what we write. In thecase of AMDL we received a fee for coverage of the current quarter in theamount of $6,000. Our reports contain factual statements and opinions. Wederive these factual statements from sources that we believe are accurate.However, we do not represent that the facts presented are accurate orcomplete. Furthermore, the information contained in this report may becomeinaccurate because of the passage of time and should therefore be read forhistorical information only.

Forward-Looking Statements: This news release contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements are subject to certain risks and uncertainties, andactual circumstances, events or results may differ materially from thoseprojected in such forward-looking statements. The Company cautions readersnot to place undue reliance on any forward-looking statements. The Companydoes not undertake, and specifically disclaims any obligation, to update orrevise such statements to reflect new circumstances or unanticipated events asthey occur.1. We feel that it is important to recognize that on an operating cash basis, AMDL came close to breaking even in the first six months of this year and will likely be even or operating cash positive by the end of the year. 2. With AMDL's most recent round of funding now completed, we look for the additional funds to enable Jade to generate net revenues for the year 2007 to $14.2 million or about double what Jade did in 2006. 3. As Jade's new distribution agreements develop their full potential, we believe that net sales will again double by the end of 2008, reaching a total of $28.4 million. That should result in gross profits for the company of about $7.1 million in 2007 and about $14.2 million in 2008. 4. We believe that Jade will be able to show a net profit at the close of 2008 of approximately $4.26 million, or 15 percent of net sales. With 12.58 million shares outstanding after the recent financing that equates to a profit of about 35 cents per share. 5. AMDL will receive FDA approval for DR-70(R) so
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cell Genesys to Present at the Bear Stearns 20th A...
S
BLU-MED Supports California's Rough & Ready Exerci...